FDA Draft Guidance on Q-Submission Program: Overview
The article provides a general overview of the revised guidance document and highlights the key points related to the existing legal framework.
The article provides a general overview of the revised guidance document and highlights the key points related to the existing legal framework.
The new article pays attention to the general questions associated with Q-Submissions that medical device manufacturers may use to request additional feedback from the authority before submitting an actual application for marketing approval.
The new article describes in detail the aspects of the different types of interactions with the authority within the Q-Submission concept, emphasizing their specific features and use cases
The new article highlights specific aspects of a clinical investigation plan, such as the approach to be followed concerning the deviations or informed consent and how it should be obtained before commencing a study.
The article highlights the critical points of managing new submissions related to the products intended to be placed on the Canadian market.
#WednesdayWebinar Join us for our upcoming webinar Global Regulatory Changes to Expect in 2025 January 22, 2025 at 10 AM ET
Register Now